Key Points Amylyx may get its flagship treatment for ALS approved by the European Medicines Agency (EMA), opening another avenue for revenue growth. Puma Biotechnology will begin a mid-stage trial for its lead cancer drug. Cassava Sciences forecasts top-line results for a Phase 3 study on its Alzheimer's disease drug to be available by the end of the calendar year. 5 stocks we like better than Amylyx Pharmaceuticals There's a reason that many biotech investors prefer to stick with large-cap stocks. Investin ...